These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17699868)

  • 1. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
    Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
    Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
    J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
    Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
    Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
    Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
    Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
    Yi X; Wei W; Wang SY; Du ZY; Xu YJ; Yu XD
    Biochem Pharmacol; 2008 May; 75(9):1697-705. PubMed ID: 18342836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.
    Yang Y; Rao R; Shen J; Tang Y; Fiskus W; Nechtman J; Atadja P; Bhalla K
    Cancer Res; 2008 Jun; 68(12):4833-42. PubMed ID: 18559531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling.
    Kekatpure VD; Dannenberg AJ; Subbaramaiah K
    J Biol Chem; 2009 Mar; 284(12):7436-45. PubMed ID: 19158084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L; Bali P; Wittmann S; Donapaty S; Guo F; Yamaguchi H; Wang HG; Atadja P; Bhalla K
    Mol Cancer Ther; 2003 Oct; 2(10):971-84. PubMed ID: 14578462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
    Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
    Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of ER alpha signaling pathway in neuronal HN10 cells: role of protein acetylation and Hsp90.
    Suuronen T; Ojala J; Hyttinen JM; Kaarniranta K; Thornell A; Kyrylenko S; Salminen A
    Neurochem Res; 2008 Sep; 33(9):1768-75. PubMed ID: 18307035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
    Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
    J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
    Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
    Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.
    Giommarelli C; Zuco V; Favini E; Pisano C; Dal Piaz F; De Tommasi N; Zunino F
    Cell Mol Life Sci; 2010 Mar; 67(6):995-1004. PubMed ID: 20039095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
    Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
    Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
    De los Santos M; Martínez-Iglesias O; Aranda A
    Endocr Relat Cancer; 2007 Dec; 14(4):1021-8. PubMed ID: 18045953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
    Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.